Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 trial of intravenous PRT060128 before primary PCI in STEMI
2007-003701-27Phase 2Active
- Sponsor
- Portola Pharmaceuticals
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of elinogrel in myocardial infarction (MI) (5 arms), sponsored by Portola Pharmaceuticals. Primary endpoints: Safety and tolerability of intravenous PRT060128 and Safety and tolerability with standard STEMI treatment. Started Oct 2007; status: active.
02
Drugs
elinogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2007-003701-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003701-27.